Overview

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Status:
Terminated

Trial end date:
2020-05-21

Target enrollment:

Participant gender:

Summary

To obtain evidence of antitumor effect of CX-072 in combination with anticancer therapy in adult patients with solid tumor based upon overall response rate by Response Evaluation Criteria in Solid Tumors (RECIST)

Phase:

Phase 2

Details

Lead Sponsor:

CytomX Therapeutics

Treatments:

Ipilimumab